Protein Sciences was founded in 1983 and has over 30 years of experience in developing vaccines and biopharmaceuticals for the prevention and treatment of a variety of diseases. They use their proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost.

Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines. Medicago Inc. has collaboration agreements with Viridis S.A.; Genopole biopark to manufacture pandemic and seasonal influenza vaccines; and Philip Morris International to produce a therapeutic protein with a humancompatible glycosylation pattern. The company was incorporated in 1997 and is headquartered in Quebec City, Canada.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

The USC Incubator accelerates the development of USC’s top student and alumni entrepreneurs through experiential education, mentorship and community. The USC Incubator, supported by the Greif Center for Entrepreneurial Studies at USC’s Marshall School takes founders from feasibility and development work, on to customers, a tested business model, getting distribution, building a team, bootstrapping and investment preparation. They also provide access to other supporting resources, such as legal and financial assistance.

Nodality, Inc., a biotechnology company, discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients. The company focuses on hematological malignancies and autoimmune disorders. Nodality, Inc. was incorporated in 2003 and is based in San Francisco, California with an additional office in Franklin, Tennessee.

Elanco U.S., Inc. develops products and services that enhance animal health, wellness, and performance. The company was founded on December 16, 1996 and is headquartered in Greenfield, IN.

Jinzhai Kuiwu Ecological Agriculture Comprehensive Development Technology Co., Ltd., established on 2013-09-23, Business scope includes agriculture,Transformation of forestry scientific and technological achievements,Promotion and base building;poultry,livestock,aquaculture,Sales and R&D;Agricultural products sales;FOOD,stay,Leisure and entertainment services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Zhuzhou Shennong Animal Pharmaceutical Co., Ltd., established on 2005-08-30, The scope of business includes the enterprise<Veterinary drug production enterprise license>Production within the approved range,Sales powder,Powder,Premix,Terminally sterilized small volume injection(Contains Chinese herbal extracts).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hunter Immunology Ltd. operates as a biotechnology company. It develops immune modulators for treatment of respiratory diseases. The company was founded by Phillip Comans in 2003 and is headquartered in Victoria, Australia.

Emergex Vaccines Holding Ltd. is a biotechnology company, which engages in the development of medicines against viral and bacterial infectious diseases. It focuses on the vaccines for dengue fever, Zika, Ebola, pandemic flu, and serious intra-cellular bacterial infections. The company was founded by Storme Moore-Thornicroft and Thomas Rademacher in 2016 and is headquartered in Abingdon, the United Kingdom.

BiomEdit LLC is a private company headquartered in Fishers, IN, that engages in designs and develops novel probiotic. It was founded by Aaron L. Schacht, he is currently the CEO of the firm.\nThe company says this about itself: BiomEdit is a microbiome innovation company that discovers, designs and develops novel probiotics, microbiome derived bioactives and engineered microbial medicines to address unmet needs in animal health. We partner with Ginkgo Bioworks to amplify and accelerate product discovery and development with a goal of introducing breakthrough innovation for livestock producers and veterinarians.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.